- Home
- LOGC vs IPHA Comparison
LOGC vs IPHA Comparison
Compare LOGC & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOGC
- IPHA
- Stock Information
- Founded
- LOGC 2010
- IPHA 1999
- Country
- LOGC United States
- IPHA France
- Employees
- LOGC N/A
- IPHA N/A
- Industry
- LOGC Catalog/Specialty Distribution
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- LOGC Consumer Discretionary
- IPHA Health Care
- Exchange
- LOGC Nasdaq
- IPHA Nasdaq
- Market Cap
- LOGC 175.8M
- IPHA 150.9M
- IPO Year
- LOGC 2020
- IPHA 2019
- Fundamental
- Price
- LOGC $7.91
- IPHA $1.95
- Analyst Decision
- LOGC
- IPHA Strong Buy
- Analyst Count
- LOGC 0
- IPHA 1
- Target Price
- LOGC N/A
- IPHA $11.50
- AVG Volume (30 Days)
- LOGC 172.4K
- IPHA 50.9K
- Earning Date
- LOGC 03-03-2025
- IPHA 03-20-2025
- Dividend Yield
- LOGC N/A
- IPHA N/A
- EPS Growth
- LOGC N/A
- IPHA N/A
- EPS
- LOGC N/A
- IPHA N/A
- Revenue
- LOGC $96,000,000.00
- IPHA $36,202,722.00
- Revenue This Year
- LOGC N/A
- IPHA N/A
- Revenue Next Year
- LOGC $422.91
- IPHA $101.65
- P/E Ratio
- LOGC N/A
- IPHA N/A
- Revenue Growth
- LOGC N/A
- IPHA N/A
- 52 Week Low
- LOGC $4.20
- IPHA $1.29
- 52 Week High
- LOGC $8.24
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- LOGC 68.64
- IPHA 56.50
- Support Level
- LOGC $7.36
- IPHA $1.72
- Resistance Level
- LOGC $6.97
- IPHA $1.92
- Average True Range (ATR)
- LOGC 0.29
- IPHA 0.11
- MACD
- LOGC 0.11
- IPHA 0.02
- Stochastic Oscillator
- LOGC 100.00
- IPHA 89.74
About LOGC ContextLogic Inc.
ContextLogic Inc is an online shopping store. The store provides personalized products, clothing products, accessories, gaming products and equipment, cosmetics, plastic products, mobile covers, and other products. Geographically, it derives a majority of its revenue from Europe and also has a presence in North America; South America, and other countries.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.